AstraZeneca’s drug Voydeya was recommended for EU approval on February 26, 2024, as an add-on treatment for adults with PNH who have ongoing symptoms despite existing therapy. This recommendation follows successful ALPHA Phase III trial results, highlighting improved health outcomes for affected patients.